513 related articles for article (PubMed ID: 9686324)
1. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
2. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.
Wabbijn M; Balk AH; van Domburg RT; Vantrimpont PJ; van Riemsdijk IC; Baan CC; Weimar W; van Gelder T
Exp Clin Transplant; 2004 Jun; 2(1):201-7. PubMed ID: 15859929
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation.
Langrehr JM; Nüssler NC; Neumann U; Guckelberger O; Lohmann R; Radtke A; Jonas S; Klupp J; Steinmüller T; Lobeck H; Meuer S; Schlag H; Lemmens HP; Knoop M; Keck H; Bechstein WO; Neuhaus P
Transplantation; 1997 Jun; 63(12):1772-81. PubMed ID: 9210503
[TBL] [Abstract][Full Text] [Related]
5. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
6. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
Guttmann RD; Flemming C
Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
[TBL] [Abstract][Full Text] [Related]
7. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
8. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
[No Abstract] [Full Text] [Related]
11. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.
Cahn JY; Bordigoni P; Tiberghien P; Milpied N; Brion A; Widjenes J; Lioure B; Michel G; Burdach S; Kolb HJ
Transplantation; 1995 Nov; 60(9):939-42. PubMed ID: 7491697
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months.
Aichberger C; Eberl T; Riedmann B; Pernthaler H; Ofner D; Königsrainer A; Margreiter R
Clin Transplant; 1996 Apr; 10(2):209-12. PubMed ID: 8664521
[TBL] [Abstract][Full Text] [Related]
13. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
Nashan B; Schlitt HJ; Schwinzer R; Ringe B; Kuse E; Tusch G; Wonigeit K; Pichlmayr R
Transplantation; 1996 Feb; 61(4):546-54. PubMed ID: 8610379
[TBL] [Abstract][Full Text] [Related]
14. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
[TBL] [Abstract][Full Text] [Related]
15. Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
Otto G; Hofmann WJ; Gaweco AS; Seelos R; Herfarth C; Meuer S
Transplant Proc; 1996 Dec; 28(6):3210-1. PubMed ID: 8962244
[No Abstract] [Full Text] [Related]
16. Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C.
Kamar N; Borde JS; Sandres-Saune K; Suc B; Barange K; Cointault O; Lavayssière L; Durand D; Izopet J; Rostaing L
Clin Transplant; 2005 Feb; 19(1):83-9. PubMed ID: 15659139
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
Glanemann M; Langrehr JM; Raakow R; Guckelberger O; Lohmann R; Klupp J; Lobeck H; Schlag H; Keck H; Bechstein WO; Settmacher U; Neuhaus P
Transplant Proc; 1998 Aug; 30(5):2159-60. PubMed ID: 9723425
[No Abstract] [Full Text] [Related]
18. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
[TBL] [Abstract][Full Text] [Related]
19. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
Cantarovich D
J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: a randomized study.
Langrehr JM; Guckelberger O; Nüssler N; Radtke A; Lemmens HP; Jonas S; Lohmann R; Tullius S; Steinmüller T; Raakow R; Neumann U; Knoop M; Bechstein WO; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3204. PubMed ID: 8962241
[No Abstract] [Full Text] [Related]
[Next] [New Search]
